Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

"Following the positive results from the previous Phase 2 and 3 studies where I previously participated in evaluating HyBryte™, we were excited to support Soligenix's effort to conduct a prospective comparative assessment of HyBryte™ versus Valchlor®," stated Dr. Brian Poligone, Director of the Rochester Skin Lymphoma Medical Group and Principal Investigator for the comparability study. "Despite the small study sample size and a randomization that lead to the HyBryte™ group having patients with more extensi ...